Eltranatamab to be made available for Australian myeloma patients
We are delighted to share that eltranatamab, an immunotherapy drug, specifically known as a bispecific antibody will be made available later in 2025 for Australian myeloma patients. This decision follows positive outcomes from a global clinical trial in which several Australian patients were participants.
The Snowdome Foundation is proud to support breakthroughs like these that accelerate next-generation treatments for Australian blood cancer patients.
Professor Miles Prince AM says …
“Doctors will call this ‘practice-changing’. The media will call it ‘game-changing’. Patients will call it ‘life-saving’.
This long-awaited news is a wonderful outcome for Australian myeloma patients.
Thank you to the entire research team for their tireless work, the Epworth Hospital for their support of this ground-breaking project and the Snowdome Foundation and their philanthropic donors.”